Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06199284Not ApplicableSuspended

Atalante Exoskeleton in the Rehabilitation of Patients With Amyotrophic Lateral Sclerosis

Role: lead

NCT03487367Unknown

Clinical Trial Readiness for SCA1 and SCA3

Role: collaborator

NCT02885870Not ApplicableCompleted

Combination of Multiparametric MRI and Electrophysiology for the Development of New Biomarkers in Spinal Cord Diseases

Role: lead

NCT03811626Not ApplicableCompleted

Efficacy of Multidimensional Management of Mild Traumatic Brain Injury

Role: lead

All 4 trials loaded